先達股份(603086.SH):截止目前烯草酮價格陸續上漲較往年相比給公司帶來較高利潤
格隆匯5月13日丨先達股份(603086.SH)在互動平臺表示,股票交易是市場行爲,公司管理層對公司經營發展非常有信心,截止目前烯草酮價格陸續上漲較往年相比給公司帶來較高利潤。公司專注創制藥的研發和產業化,今年公司創新藥吡唑喹草酯投放市場,目前公司已有喹草酮、吡唑喹草酯兩款創制藥,苯丙草酮處於待評審階段。第一季度已啓動兩款創制藥登記程序,未來創新藥方面將給公司發展注入持續發展動力,請持續關注公司發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.